SKAN Group AG (SKAN) AI Stock Analysis

• Market Cap: CHF1.31B
• Dividend Yield: 0.77%
• Average Volume (3M): 22.50K
• Price to Earnings (P/E): 80.2
• Beta (1Y): 0.83
• Revenue Growth: -3.45%
• EPS Growth: -49.82%
• Country: CH
• Employees: 1,377
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.40
• Shares Outstanding: 22,483,524
• 10 Day Avg. Volume: 19,367
• 30 Day Avg. Volume: 22,504
• PEG Ratio: 0.92
• Price to Book (P/B): 8.73
• Price to Sales (P/S): 4.74
• P/FCF Ratio: -241.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF71.00
• Price Target Upside: 30.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: CHF60.00 ▲(10.09% Upside)

SKAN Group AG's strong financial performance is overshadowed by bearish technical indicators and high valuation metrics. The stock's overvaluation and negative market momentum are significant concerns, despite its solid financial health.

Positive Factors

Robust Profitability and Margins

Sustained gross and net margins indicate durable cost management and pricing power in highly regulated aseptic equipment. Strong EBIT/EBITDA margins support reinvestment in engineering and services, enhancing long-term competitiveness and cash generation resilience.

Stable Balance Sheet and Equity Base

A solid equity ratio and reasonable debt-to-equity imply prudent leverage and financial stability. This balance-sheet strength preserves access to financing, supports large project deliveries, and reduces solvency risk across multi‑year equipment install cycles.

Recurring After-sales and Lifecycle Services

A meaningful services revenue stream tied to installed equipment creates recurring, higher-margin cash flows and customer lock-in via maintenance, parts, and upgrades. This stabilizes revenue across project cycles and strengthens long-term profitability visibility.

Negative Factors

Weak Recent Revenue and EPS Trends

Negative top-line growth and a steep EPS decline signal demand or execution headwinds that can persist across quarters. Prolonged revenue or earnings contraction reduces retained earnings and limits capacity to invest in R&D, services expansion, or strategic initiatives.

Free Cash Flow Pressure from High CapEx

Persistently negative free cash flow driven by elevated capex can erode liquidity and force trade-offs between servicing debt, funding growth projects, or expanding services. Over time this strains financial flexibility and increases reliance on external financing.

Growing Total Liabilities

Rising total liabilities increase balance-sheet risk and may raise fixed financing costs. If liabilities grow faster than assets or earnings, leverage and interest burden can limit strategic options like M&A or capex, weakening long-term resilience against demand shocks.

SKAN Group AG Business Overview & Revenue Model

Company Description

SKAN Group AG provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Asia, Europe, the Americas, and internationally. It operates in two segments: Equipment and Solutions (E&S) and Services and Consumables (S&C). The E&S segment offers mission-critical solutions for the pharmaceutical production, including isolators, integrated automated systems, and aseptic filling systems and solutions, as well as laboratory and cleanroom equipment. The S&C segment provides life cycle support and ready-to-use consumables, as well as customer- specific and digital solutions. The company was formerly known as BV Holding AG and changed its name to SKAN Group AG in October 2021. SKAN Group AG was founded in 1968 and is headquartered in Allschwil, Switzerland.

How the Company Makes Money

SKAN generates revenue through multiple streams, primarily from the sale of its modular cleanroom systems and containment solutions, which are essential for maintaining sterile environments in pharmaceutical production. The company also earns income through consulting services that assist clients with regulatory compliance, process validation, and optimization. Additionally, SKAN engages in partnerships with key players in the pharmaceutical sector, enhancing its market reach and client base. The company may also benefit from ongoing maintenance contracts and training services, which provide recurring revenue opportunities. Overall, SKAN's focus on high-quality engineering solutions and customer service positions it well to capitalize on the growing demand in the pharmaceutical and biotechnology industries.

SKAN Group AG Financial Statement Overview

Summary

SKAN Group AG shows strong financial performance with robust revenue and profit growth. The income statement is impressive, and the balance sheet is stable, though cash flow management needs improvement due to high capital expenditures.

Income Statement

SKAN Group AG has demonstrated strong revenue growth, with Total Revenue increasing consistently over the years. The Gross Profit Margin and Net Profit Margin have remained robust, indicating effective cost management and profitability. The EBIT and EBITDA margins are healthy, showcasing operational efficiency. Overall, the company displays a solid income statement performance with positive growth trends.

Balance Sheet

The company's balance sheet is stable, supported by a reasonable Debt-to-Equity Ratio, indicative of prudent leverage levels. The Return on Equity is strong, reflecting good profitability relative to equity. The Equity Ratio shows a solid equity base compared to total assets, enhancing financial stability. However, some attention is needed on total liabilities, which have grown over time.

Cash Flow

SKAN Group AG's cash flow performance is mixed, with fluctuating free cash flow levels. The Operating Cash Flow to Net Income Ratio is favorable, showing effective cash generation from operations. However, recent negative Free Cash Flow suggests high capital expenditures impacting cash reserves. The company needs to manage investing activities to maintain liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	332.13M	361.30M	320.02M	276.95M	234.26M	191.69M
Gross Profit	240.89M	265.88M	234.08M	200.50M	170.11M	133.00M
EBITDA	36.38M	59.68M	50.14M	40.15M	32.38M	16.48M
Net Income	16.18M	38.80M	26.31M	18.99M	10.62M	4.53M
Balance Sheet
Total Assets	381.49M	384.49M	373.45M	388.35M	331.92M	259.54M
Cash, Cash Equivalents and Short-Term Investments	52.94M	61.71M	85.12M	135.98M	131.54M	63.82M
Total Debt	10.02M	10.61M	6.49M	16.88M	15.27M	7.45M
Total Liabilities	198.06M	181.92M	197.09M	222.76M	157.92M	176.98M
Stockholders Equity	177.16M	196.16M	169.23M	157.30M	159.75M	41.65M
Cash Flow
Free Cash Flow	18.38M	-7.09M	-26.60M	32.62M	-32.29M	8.07M
Operating Cash Flow	68.58M	46.70M	8.70M	61.48M	10.32M	22.63M
Investing Cash Flow	-52.28M	-69.06M	-17.35M	-76.42M	-11.02M	-15.95M
Financing Cash Flow	-10.54M	-9.35M	-15.80M	-4.85M	67.48M	-8.15M

SKAN Group AG Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 54.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SKAN, the sentiment is Neutral. The current price of 54.5 is below the 20-day moving average (MA) of 57.21, above the 50-day MA of 52.38, and below the 200-day MA of 61.33, indicating a neutral trend. The MACD of 1.93 indicates Positive momentum. The RSI at 57.30 is Neutral, neither overbought nor oversold. The STOCH value of 41.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:SKAN.

SKAN Group AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SFSN	72 Outperform	CHF4.41B	18.74	―	1.85%	-0.71%	-6.12%
STMN	72 Outperform	CHF14.84B	37.19	―	1.02%	4.49%	45.08%
YPSN	70 Outperform	CHF4.16B	21.60	27.15%	0.67%	27.63%	160.67%
TECN	65 Neutral	CHF1.74B	27.45	4.57%	2.31%	-9.34%	-37.50%
COTN	64 Neutral	CHF2.33B	58.89	―	0.68%	27.24%	122.39%
SKAN	55 Neutral	CHF1.31B	80.19	―	0.77%	-3.45%	-49.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

SKAN Group AG Corporate Events

SKAN Group Taps Digital Expert for Board as Long-Serving Director Steps Down

SKAN Group AG is strengthening its governance and digital capabilities by nominating software and AI specialist Dr. Christian Schlögel to its Board of Directors, subject to shareholder approval at the 7 May 2026 Annual General Meeting, while long-serving board member and financial expert Patrick Schär steps down after 16 years. The appointment aligns with SKAN’s strategic push into software and digital integration services, including last year’s majority stake acquisition in Metronik, and is intended to accelerate the company’s digital transformation and support future revenue and margin growth, signalling a deliberate shift toward more technology-driven solutions in its aseptic processing niche.

The most recent analyst rating on (CH:SKAN) stock is a Sell with a CHF58.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.

SKAN signals lower 2025 earnings despite resilient order intake

SKAN Group AG announced provisional, unaudited figures for its 2025 financial year, indicating a decline in net sales to around CHF 332 million from CHF 361.3 million in 2024 and a sharper drop in EBITDA to approximately CHF 38 million from CHF 57.0 million, while order intake slightly increased to around CHF 365 million from CHF 359.5 million. The detailed 2025 annual results and accompanying annual report will be published on 24 March 2026, when management is also set to brief investors, analysts and media in Zurich, giving stakeholders further insight into the drivers of the weaker profitability against a stable demand backdrop.

The most recent analyst rating on (CH:SKAN) stock is a Sell with a CHF58.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.

SKAN Group AG Adjusts 2025 Financial Expectations Amid Project Delays

SKAN Group AG announced that it will not meet its revenue and profit expectations for 2025 due to project delays, resulting in a decline in net revenue and a lower EBITDA margin for the year. Despite these setbacks, the company reports a positive order intake, particularly in oncology and biotechnology sectors, laying a strong foundation for a successful fiscal year 2026. The company’s medium- and long-term growth prospects remain positive, supported by structural market growth and a robust project pipeline.

The most recent analyst rating on (CH:SKAN) stock is a Hold with a CHF57.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.